6149fed5aa40346ca98899b3 fda-approves-exelixis-cabometyx-for-differentiated-thyroid-cancer 2021-09-21T20:06:56.299Z 5e283dc93b5e750642253d73 3cc45ece-e3d4-40fc-960b-5f2c436c1ed2 8f13726e-5635-471f-ad3c-fc910a6ac2b1 mas_evidence_types:Media%20and%20commentaries Media and commentaries Approx 5% to 15% of cases are resistant to radioiodine treatment, with life expectancy of 3 to 5 years. Trial evaluating Cabometyx in this population met 1of the 2 primary endpoints of significant improvement versus placebo in progression-free survival (11.0 vs.1.9 months). <p>Final of phase 3 COSMIC-311 pivotal trial (n=258) have been presented at conference. At a median follow-up of 10.1 months, Cabometyx reduced the risk of disease progression or death versus placebo (HR 0.22; 96% CI, 0.15&ndash;0.32) in the intent-to-treat (ITT) population.</p> https://www.medicinesresources.nhs.uk/fda-approves-exelixis-cabometyx-for-differentiated-thyroid-cancer.html <p><a href="https://www.biospace.com/article/releases/exelixis-announces-final-results-from-phase-3-cosmic-311-pivotal-trial-of-cabometyx-in-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer-presented-at-esmo-2021/">Conference report: final result from phase 3 COSMIC-311 study</a></p> http://www.pharmatimes.com/news/fda_approves_exelixis_cabometyx_for_differentiated_thyroid_cancer_1378154 2021-09-20T00:00:00Z 2021-09-21T15:48:37.98Z